LBA-001Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). (24th June 2018)

Record Type:: Journal Article
Title:: LBA-001Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). (24th June 2018)
Main Title:: LBA-001Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
Authors:: Zhu, A
Finn, R
Galle, P
Llovet, J
Blanc, J F
Okusaka, T
Chau, I
Abada, P
Hsu, Y
Kudo, M
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 5
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 5
Issue Display:: Volume 29, Issue 5 (2018)
Year:: 2018
Volume:: 29
Issue:: 5
Issue Sort Value:: 2018-0029-0005-0000
Page Start:
Page End:
Publication Date:: 2018-06-24
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy208 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12158.xml